J Allergy Clin Immunol:高IL-17型哮喘患者具有银屑病免疫表型

2020-09-30 MedSci原创 MedSci原创

IL-17免疫在银屑病、炎症性肠病等炎症性疾病患者中的作用已得到充分肯定,但在哮喘患者中的作用并不明显,需要进一步研究。本研究旨在对IL-17免疫性上调的哮喘患者进行深入的表型研究,研究结果已在线发表

IL-17免疫在银屑病、炎症性肠病等炎症性疾病患者中的作用已得到充分肯定,但在哮喘患者中的作用并不明显,需要进一步研究。本研究旨在对IL-17免疫性上调的哮喘患者进行深入的表型研究,研究结果已在线发表于J Allergy Clin Immunol。

通过上皮刷片、支气管活检标本(91名哮喘患者和46名健康对照组受试者)和全血样本(n = 498)进行全基因组转录组分析,这些样本来自预测呼吸系统疾病结果的无偏生物标志物(U-BIOPRED)队列。使用支气管上皮细胞中IL-17和IL-13在体外诱导的基因标志来鉴定具有IL-17高和IL-13高哮喘表型的患者。

 

结果,91名患者中,分别有22名和患者9名患者被鉴定出IL-17和IL-13基因标志。高IL-17哮喘患者的特点是频繁发作、气道(痰和粘膜)中性粒细胞增多、肺微生物群多样性降低,以及血栓素B2通路激活的尿液生物标志物的风险。在通路分析中,高IL-17哮喘患者中差异表达的基因与银屑病皮损改变的基因有共同之处,包括调节上皮屏障功能和防御机制的基因,如IL1B、IL6、IL8和β-防御素。

 

综上所述,该研究结果表明,高IL-17哮喘表型以支气管上皮功能障碍和抗菌和炎症反应上调为特征,与银屑病的免疫表型相似,包括血栓素B2通路的激活,在进一步的研究中,包括针对IL-17的临床试验中,应将其视为该表型的生物标志物。

 

原始出处:

 

Jörgen ÖstlingMarleen van Geest, et al., IL-17-high asthma with features of a psoriasis immunophenotype. J Allergy Clin Immunol. 2019 Nov;144(5):1198-1213. doi: 10.1016/j.jaci.2019.03.027.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1329420, encodeId=7a701329420d8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374445, encodeId=0cda13e444553, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508295, encodeId=dc93150829554, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535282, encodeId=3dd915352821f, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2020-10-02 膀胱癌
  2. [GetPortalCommentsPageByObjectIdResponse(id=1329420, encodeId=7a701329420d8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374445, encodeId=0cda13e444553, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508295, encodeId=dc93150829554, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535282, encodeId=3dd915352821f, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2020-10-02 fzwish20000
  3. [GetPortalCommentsPageByObjectIdResponse(id=1329420, encodeId=7a701329420d8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374445, encodeId=0cda13e444553, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508295, encodeId=dc93150829554, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535282, encodeId=3dd915352821f, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2020-10-02 jjjiang0202
  4. [GetPortalCommentsPageByObjectIdResponse(id=1329420, encodeId=7a701329420d8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374445, encodeId=0cda13e444553, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508295, encodeId=dc93150829554, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535282, encodeId=3dd915352821f, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Fri Oct 02 14:03:45 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2020-10-02 tastas

相关资讯

Ann Rheum Dis :西湖大学郑厚峰团队阐明银屑病型关节炎和骨质疏松的关系

银屑病是一种常见的自身免疫性皮肤病,在欧洲人群的发病率是2.5%,亚洲人群发病率是0.1%-0.5%,其中最严重的并发症是银屑病性关节炎。目前对银屑病是否能够导致骨质疏松依旧存在着争议。

Ann Rheum Dis: 西湖大学郑厚峰团队阐明银屑病型关节炎和骨质疏松的关系

他们研究发现,银屑病性关节炎(Psoriatic arthritis)患者与对照组相比,骨量明显减少,但这个关联关系并不由遗传因素决定,也就是不具有归因关系.

JAHA:银屑病对心肌梗死患者死亡率和结局的影响

在所有MI病例中,只有0.3%的患者被诊断为银屑病,而患有银屑病的MI患者比没有银屑病的MI患者中位年龄要小5岁。银屑病似乎可以增加已知心血管危险因素的患病率。

FDA和EMA已接受bimekizumab治疗银屑病的市场营销申请

美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)均已接受UCB制药公司的银屑病治疗药物bimekizumab的市场营销申请。

诺华IL-17A单抗Cosentyx:获欧盟批准一线治疗牛皮癣儿童患者

59.5%的儿童在治疗后第12周获得了完全透明的皮肤(PASI 100)。

Ann Rheum Dis:银屑病、银屑病关节炎与骨质疏松症之间的关系

综上所述,PsA对骨质疏松的影响是继发性的(例如药物治疗),并不存在因果关系。